Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study

American Cancer Society. Cancer facts and figures 1995. Atlanta: American Cancer Society, 6, 1995.

DiSaia P.J. , Creasman W.T. : Clinical gynecologic oncology. Mosby-Year Book, Inc, pp 282–350, St. Louis, Missouri, 1997.

Mant J.W.F. , Vessey M.P. : Ovarian and endometrial cancers. Cancer surveys trends in cancer incidence and mortality, 9: 287–307, 1994.

Yancik R. : Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer, 71: 517–523, 1993.

Longo D.L. , Young R.C. : The natural history and treatment of ovarian cancer. (Review). Annu Ver Med, 32: 475–490, 1981.

Deraco M. , Santoro N. , Carraro O. , Inglese M.G. , Rebuffoni G. , Guadagni S. , Carlier Somers D. , Vaglini M. : Peritoneal carcinomatosis: features of dissemination. (Review). Tumori, 85: 1–5, 1999.

Markman M. : Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. [Review]. Semin Oncol, 21(2 suppl 2): 17–19, quiz 20, 58, 1994.

Sugarbaker P.H. , Graves T. , De Bruijn E.A. , Cunliffe W.J. , Mullins R.E. , Hull W.E. , Oliff L. , Schlag P. : Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis form gastrointestinal cancer: pharmacological studies. Cancer Res, 50: 5790, 1990.

Alberts D.S. , Liu P.Y. , Hannigan E.V. : Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) in patients with optimal disease stage III ovarian cancer: a AWOG-GOG-ECOG intergroup study. Proc ASCO, 14: 273 [Abstract], 1995.

Howell S.B. , Kirmai S. , McClay E.F. , Kim S. , Braly P. , Plaxe S. : Intraperitoneal cisplatin based chemotherapy for ovarian carcinoma. Semin Oncol, 18(1 suppl 3): 5–10, 1991.

Howell S.B. , Zimm S. , Markman M. , Abramson I.S. , Clearly S. , Lucas W.E. , Weiss R.J. : Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol, 5: 1607–1612, 1987.

Markman M. : Intraperitoneal chemotherapy. Semin Oncol, 18: 248–254, 1991.

Engelhardt R. : Hyperthermia and drugs. Recent Results Cancer Res, 104: 136–203, 1987.

Teicher B.A. , Kowal C.D. , Kennedy K.A. , Sartorelli A.C. : Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res, 41: 1096–1099, 1981.

Hettinga J.V.E. , Lemstra W. , Meijer C. , Dam W.A. , Uges D.R.A. , Konings A.W.T. , Vries E.G.E. , Kampinge H. : Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br J Cancer, 75: 1735–1743, 1997.

Bozzetti F. , Vaglini M. , Deraco M. : Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori, 84: 483–488, 1998.

Gomes Portilla A. , Deraco M. , Sugarbaker P.H. : Clinical pathway for peritoneal carcinomatosis from colon and rectal cancer: guidelines for current practice. Tumori, 83: 725–728, 1997.

Koga S. , Hamazoe R. , Maeta M. , Shimizu N. , Murakami A. , Wakatsuki T. : Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with MMC. Cancer, 61: 232–237, 1988.

Yonemura Y. , Fujimura T. , Fushida S. , Takegawa S. , Kamata T. , Katayama K. , Kosaka T. , Yamaguchi A. , Miwa K. , Miyazaki I. : Hyperthermia-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg, 15: 530–536, 1991.

Deraco M. , Vaglini M. , Santinami M. , Santoro N. , Inglese M.G. , Spatti G.B. : Intraperitoneal hyperthermic perfusion (IPHP): analysis of morbidity and toxicity. Oncol Rep, 3: 1103–1106, 1996.

Kober F. , Heiss A. , Roka R. : Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemope-rfusion. Cancer Treat Res, 82: 211–219, 1996.

Salle B. , Gilly F.N. , Carry P.Y. , Sayag A. , Brachet A. , Braillon G. : Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, phys-iopathologic data. J Gynecol Obstet Biol Reprod (Paris), 22: 369–371, 1993.

Steller M.A. , Egorin M.J. , Trimble E.L. , Bartlett D.L. , Zuhowski E.G. , Alexander H.R. , Dedrick R.L. : A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol, 43: 106–114, 1999.

Vaart P.J.M. , Vange N. , Zoetmulder F.A.N. , Goethem A.R. , Tellin-gen O. , ten Bokkel Huinink W.W. , Beijnen J.H. , Bartelink H. , Begg A.C. : Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer, 34: 148–154, 1998.

Japanese Research Society for Gastric Cancer (1981): The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg, 11: 127–139, 1981.

Jacquet P. , Sugarbaker P.H. : Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res, 15: 49–58, 1996.

McGuire W.P. , Hoskin W.J. , Brady M.F. , Kucera P.R. , Patridge E.E. , Look K.Y. , Clarke-Pearson D.L. , Davidson M. : Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med, 334: 1–6, 1996.

Ozols R.F. , Young R.C. : Ovarian cancer. Curr Probl Cancer, 11: 57–122, 1988.

Dauplat J. , Ferriere J.P. , Gorbinet M. , Legros M. , Chollet P. , Gikaud B. , Plagne R. : Second look laparotomy in managing epithelial ovarian carcinoma. Cancer, 57: 1627–1631, 1986.

De Gramont A. , Drolet Y. , Lavoie A. , Painchaud M. , Blouin R. , Tessier C. , Ouellet P. : Adriamycin and cisplatinum in advanced ovarian cancer. Eur J Cancer Clin Oncol, 21: 665–669, 1985.

Louie K.G. , Ozols R.F. , Myers C.E. , Ostchega Y. , Jenskins J. , Howser D. , Young R.C. : Long-term results of a cisplatin-con-taining combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol, 4: 1579–1585, 1986.

Neijt J.P. , ten Bokkel Huinink W.W. , Van der Burg M.E. , van Oosterom A.T. , Willemse P.H. , Heintz A.P. , van Lent M. , Trimbos J.B. , Bouma J. , Vermoken J.B. : Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. J Clin Oncol, 5: 1157–1168, 1987.

Pasmantier M.W. , Coleman M. , Silver R.T. , Perry Ballard W. : Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. Cancer Treat Rep, 69: 689–693, 1985.

Steiner M. , Rubinov R. , Borovik R. , Cohen Y. , Robinson E. : Multimodal approach (surgery, chemotherapy and radiotherapy) in the treatment of advanced ovarian carcinoma. Cancer, 55: 2748–2752, 1985.

Wils J. , Blijham G. , Naus A. , Belder C. , Boschma F. , Bron H. , Ceelen T. , Eekhout A. , von Erp J. , Geelen P. , Geuns H.V. , Hoest J. , Hoogland H. , Huiskes J. , de Koning Gans H. , Kornman J. , Kruyerer G. , Lalisang F. , Meulen J.V.D. , Moorman P. , de Pree N. , Stoot J. , Tushuizen P. , Vreeswijk J. , Wals J. , Wetzels L. , Willebrand D. : Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cy-closphosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol, 4: 1068–1073, 1986.

De Gramont A. , Drolet Y. , Varette C. , Louvet C. , Gonzalez-Canall G. , Krulik M. , Cady J. , Pigne A. , Marpeau L. , Barrat J. , Gallot D. , Malafosse M. , Debray J. : Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J Cancer Clin Oncol, 25: 451–457, 1989.

Gershenson D.M. , Copeland L.J. , Wharton J.T. , Atkinson E.N. , Sneige N. , Edwards C.L. , Rutledge F.N. : Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer, 5: 1129–1135, 1985.

Neijt J.P. , ten Bokkel Huinik W.W. , Van der burg M.E.L. , Van Oosterrom A.T. : Complete remission at laparotomy: still a gold standard in ovarian cancer? Lancet, 1 (8488): 1028, 1986.

Look K.Y. , Muss H.M. , Blessing J.A. , Morris M. : A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Clinical Oncol, 18: 19–22, 1995.

Lorusso V. , Catino A. , Leone B. , Rabinovich M. , Gargano G. , Paradiso A. , De Lena M. : Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol, 11: 1952–1956, 1995.

Markman M. , Reichman B. , Hakes T. , Jones W. , Lewis J.L. Jr. , Rubin S. , Almadronesi L. , Hoskins W. : Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol, 9: 1801–1805, 1991.

Piver M.S. , Recio F.O. , Baker T.R. , Driscoll D. : Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian. Cancer, 73: 1693–1698, 1994.

Stiff P.J. , Bayer R. , Kerger C. , Potkul R.K. , Malhotra D. , Peace D.J. , Smith D. , Fisher S.G. : High-dose chemotherapy with autologous transplantation for persistent /relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol, 15: 1309–1317, 1997.

ten Bokkel Huinink W.W. , Gore M. , Carmichael J. , Gordon A. , Malfetano J. , Hudson I. , Broom C. , Scarabelli C. , Dawidson N. , Spanczynski M. , Bolis G. , Malmstrom H. , Coleman R. , Fields S.C. , Heron J.F. : Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 15: 2183–2193, 1997.

Trimble E.L. , Adams J.D. , Vena D. , Hawinks M.J. , Friedman M.A. , Fisherman J.S. , Christian M.C. , Canetta R. , Onetto N. , Hayn R. : Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Referral center 9103. J Clin Oncol, 11: 2405–2410, 1993.

Vergote I. , Himmelmann A. , Frankendal B. , Scheistroen M. , Vlachos K. , Trope C. : Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol, 47: 282–286, 1992.

Berek J.S. , Hacker N.F. , Lagasse L.D. , Nieberg R.K. , Elashoff R.M. : Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol, 61: 189–193, 1983.

Eisenkop S.M. , Friedman R.L. , Wang H. : Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer, 76: 1606–1614, 1995.

Janicke F. , Holscher M. , Kuhn W. , von Hugo R. , Pache L. , Siewert J.R. , Graeff H. : Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer, 70: 2129–2136, 1992.

Morris M. , Gershenson D.M. , Wharton J.T. , Copeland L.J. , Edwards C.L. , Stringer C.A. : Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol, 34: 334–338, 1989.

Segna R.A. , Dottino P.R. , Mandeli J.P. , Konsker K. , Cohen C.J. : Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol, 11: 434–439, 1993.

Vaccarello L. , Rubin S.C. , Vlamis V. , Wong G. , Jones W.B. , Lewis J.L. , Hoskins W.J. : Cytoreductive surgery in ovarian carcinoma patients with documented previously complete surgical response. Gynecol Oncol, 57: 61–65, 1995.

Goldie J.H. , Coldman J.A. : A mathematics model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 63: 1727–1733, 1979.

Jacquet P. , Sugarbaker P.H. : Peritoneal-plasma barrier. In: Peritoneal carcinomatosis: principles of management, Sugarbaker Ph (Ed), pp. 53–63, Kluwer Academic Publishers, Boston, 1966.

Deraco M. , Vaglini M. , Santinami M. , Costagli V. , Di Re F. , Inglese M.G. , Mascotti G. , Persiani L. , Santoro N. , Sequeira C. , Carlier-Somers D. : Razionale per un trattamento chemioiper-termico della carcinosi peritoneale. Arg Oncol, 16: 149–159, 1995.